Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eryaspase plus chemotherapy versus chemotherapy alone as second-line treatment for pancreatic adenocarcinoma
NL-OMON55526Phase 3Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Nov 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of eryaspase in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by PHAXIAM Therapeutics. Primary endpoint: Overall survival. Started Nov 2019; status: completed.
02
Drugs
eryaspase
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON55526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55526.